Hikal Q1FY27: consolidated loss narrows to ₹7.4 Cr YoY as margins expand, revenue up 6%

Hikal's consolidated Q1 FY27 revenue rose 5.9% YoY to ₹402.8 Cr (₹403 Cr per management's release) but fell 22.4% QoQ from the seasonally heavier ₹519.4 Cr booked in Q4 FY26. The company posted a consolidated net loss of ₹7.4 Cr, narrower than the ₹22.4 Cr loss a year ago and a swing from the ₹14.4 Cr profit in Q4 FY26. NPM was -1.8%, improved from -5.9% YoY but down from +2.7% in Q4. No consensus/Street estimates for this quarter turned up in available previews, so the print cannot be benchmarked against Street numbers; management's own release headlined revenue and a 260 bps YoY EBITDA margin expansion without flagging the continuing bottom-line loss.

The quarter was flattered by a ₹8.9 Cr exceptional gain (restructured salary components reduced a labour-code related liability); stripping this out, the pre-exceptional PBT loss was ₹18.8 Cr — still narrower than the ₹30.4 Cr adjusted loss a year ago (~27% improvement) but far more modest than the 67% narrowing the reported PAT shows. By segment, Pharmaceuticals turned a ₹7.5 Cr profit on ₹233.3 Cr revenue while Crop Protection swung to a ₹6.0 Cr segment loss on ₹169.5 Cr revenue versus a ₹17.3 Cr profit a year ago, reversing the mix that supported FY26. Finance costs (₹14.9 Cr) and depreciation (₹42.7 Cr) remain a heavy drag below the operating line. This sits against May 2026 guidance for a stronger FY27 on positive volume growth and margins sustaining at improved levels through operating leverage — the YoY margin expansion is broadly consistent with that framing, but the ongoing net loss and the Crop Protection swing to a loss fall short of a 'stronger year' start. The USFDA warning letter on the Jigani facility (since August 2025) continues to weigh on Pharma segment sales, per the company's own disclosure.

The stock went into the print at ₹221.43, down 3.2% over the past month of trading.